Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.39 |
| ▸ | FNTB | P49356 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1948541 | 0.94 | FNTA (0.39) | FNTAFNTBDRD2DRD4PGGT1B | |
| SCHEMBL1947912 | 0.88 | ESR2 (0.46) | FNTAFNTBPGGT1BTP53LMNA | |
| SCHEMBL1951599 | 0.86 | DRD2 (0.40) | DRD2DRD4GPR119THRBTP53 | |
| SCHEMBL2641040 | 0.83 | MEN1 (0.41) | FNTAFNTBDRD2DRD4MEN1 | |
| SCHEMBL1948520 | 0.80 | ALDH1A1 (0.36) | DRD2DRD4GPR119THRBTP53 | |
| SCHEMBL1951261 | 0.80 | DRD2 (0.38) | DRD2DRD4MEN1KMT2AOXTR | |
| SCHEMBL1723122 | 0.80 | FNTA (0.55) | FNTAFNTBPGGT1BLMNAMEN1 | |
| SCHEMBL1949522 | 0.79 | LMNA (0.42) | LMNAMEN1KMT2AALDH1A1GAA | |
| SCHEMBL3376298 | 0.78 | FNTA (0.48) | FNTAFNTBPGGT1BLMNAMEN1 | |
| SCHEMBL1949362 | 0.77 | LMNA (0.45) | TP53LMNAMEN1KMT2AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438055-B1 | DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | JAPAN TOBACCO INC (JP) | 2018-10-24 | — | — | EP | disclosed |
| US-8426442-B2 | Compounds | XENTION LTD (GB) | 2013-04-23 | — | — | US | disclosed |
| US-20110136860-A1 | Compounds | XENTION LTD. (GB) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136860-A1 | Compounds | NR3C2, NR5A1, NR0B2 | FNTA 1682/4885FNTB 2328/4885DRD2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.